Prostate cancer (PCa) is the most common cancer diagnosis with highly heterogeneous properties and the second leading cause of cancer-related death behind lung cancer. Despite many advances in diagnosis and management, the morbidity rate of prostate cancer still remains high due to high false positive rates in the diagnosis and the therapy resistance development to androgen suppression which known as androgen deprivation therapy (ADT), a standard care for the initial management of PCa. There has been reported the multiple underlying mechanisms that result in the progression of castration-resistance prostate cancer (CRPC) within 12 to 18 months of initiation of ADT. The metastatic PCa requires with very limited options except for docetaxel chemotherapy. For that reason, it has been extensively focused on the development of combined strategy with the accurate diagnosis and therapies for effective cancer treatment before drug resistance emergence<br/> <br/>We have developed the targeted nano-theranostic platform to address the challenges associated with the accurate diagnosis and efficient drug delivery for early-staged cancer treatment. The nanoconstruct is prepared by assembled hydrophobic magnetic nanoparticles with phospholipid which provides the theranostic system with three distinct functional features: (1) a magnetic core part for the visualization tumor site in soft tissue and monitoring tumor size during therapy; (2) targeting ligand for specific tumor targeting and accurate diagnosis; and (3) lipophilic pocket for high drug payload and the increased drug efficacy with low chemotherapy side effect. In a diagnostic perspective, the nanoplatform functionalized with aptamer was demonstrated to target prostate cancer cell and show the enhanced contrast in MRI. Importantly, the platform improved the drug efficacy of the anti-cancer agent, curcumin (Cur), when harnessed as a Cur delivery carrier. We expect that the smart nanotheranostic platform could be of interest in the early cancer treatment and diagnostics.<br/>

Magnetic nanostructures (MNS) as theranostic agents for early stage prostate cancer

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.